← 返回

急性髓系白血病中 NK 细胞和 T 细胞抑制性检查点 LAG-3、TIM-3 和 PD-1 的表达:LAG-3 表达的保留与患者生存相关

英文原题:Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival.

查看英文原题

Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival.

PubMed 2025/10/06(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

急性髓系白血病(AML)是成人中最常见的白血病类型。尽管治疗取得了进展,但诊断后的平均生存率仍然很低。AML还会改变患者的免疫反应,进一步促进疾病进展。

本研究的目的是分析新诊断AML患者NK细胞和T细胞上LAG-3、TIM-3和PD-1抑制性检查点的表达及其对患者生存的影响。与健康供者相比,AML患者的NK细胞和T细胞显示TIM-3表达较低,而LAG-3的表达未观察到显著差异。共表达这些受体的细胞百分比显示,与健康供者相比,AML患者中LAG-3 + TIM-3 + PD-1 - NK和T细胞的百分比降低。

值得注意的是,根据这些受体的表达对AML患者进行的生存分析显示,NK细胞和T细胞上LAG-3的高表达与更好的生存相关。此外,那些NK和T细胞上LAG-3和TIM-3共表达较高的AML患者比LAG-3和TIM-3共表达较低的患者生存更好(超过6个月),因此支持这些检查点受体表达较低的NK和T细胞的扩增反映了一种与不良预后相关的功能障碍状态。

本研究确定了NK和T细胞上LAG-3和TIM-3检查点的表达作为AML预后的潜在生物标志物,有助于确定那些可能从检查点阻断疗法中获益的患者。

展开英文摘要原文

Acute myeloid leukemia (AML) is the most common type of leukemia in adults. Despite advances in treatment, the average survival rate after diagnosis is low. AML also alters the patient's immune response further contributing to disease progression. The aim of this study was to analyze the expression of LAG-3, TIM-3 and PD-1 inhibitory checkpoints on NK cells and T cells from newly diagnosed AML patients and its impact in patient survival.

NK cells and T cells from AML patients showed a lower expression of TIM-3 compared with healthy donors, whereas no significant differences were observed in the expression of LAG-3. The percentages of cells co-expressing these receptors showed a decrease in the percentage of LAG-3 + TIM-3 + PD-1 - NK and T cells from AML patients in comparison with healthy donors.

Remarkably, the survival analysis of AML patients according to the expression of these receptors showed that higher expression of LAG-3 on NK cells and T cells was associated with better survival.

In addition, those AML patients showing higher co-expression of LAG-3 and TIM-3 on NK and T cells had better survival (higher than 6 months) than those with lower co-expression of LAG-3 and TIM-3, therefore supporting that the expansion of NK and T cells with lower expression of these checkpoint receptors reflects a dysfunctional state associated with poor prognosis.

This study identifies the expression of LAG-3 and TIM-3 checkpoints on NK and T cells as potential biomarkers of AML prognosis, contributing to define those patients that could benefit from checkpoint blockade therapies.

论文信息

作者
Valhondo I、Pera A、Hassouneh F、López-Sejas N、Álvarez-Heredia P、Bergua JM、Arcos MJ、Casas-Avilés I
第一作者单位
Área de Inmunología, Departamento de Fisiología, Universidad de Extremadura, 10003, Cáceres, Spain.Spain
通讯作者单位
Área de Inmunología, Departamento de Fisiología, Universidad de Extremadura, 10003, Cáceres, Spain. rtarazon@unex.es.Spain
期刊
Cancer immunology, immunotherapy : CII2025 Oct 6
原文标识
PubMed 41051510 · DOI 10.1007/s00262-025-04169-y